Business
Pfizer signs up to access Chai Discovery's generative AI platform for next-gen antibody design
Pfizer (NYSE: PFE) has licensed San Francisco-based Chai Discovery's generative AI platform — including early access to Chai-3, a previously undisclosed...
Everest Medicines licenses Bejescin from Beijing Mabworks for Asia-Pacific commercialization
Everest Medicines (HKEX: 1952.HK) has secured exclusive rights to develop and commercialize Bejescin (MIL62, obinutuzumab beta injection) across the...
SOPHiA Genetics and Memorial Sloan Kettering form joint venture for precision oncology AI analytics
SOPHiA Genetics and Memorial Sloan Kettering move toward joint venture for precision oncology
Lilly's Korean siRNA parnter OliX raises USD 80m in PIPE funding
South Korea-based OliX Pharmaceuticals, Inc. (KOSDAQ: 226950) announced a private placement of newly issued common shares raising approximately KRW 110...
Regeneron expands CytomX collaboration to USD 4b for conditional bispecific cancer therapeutics
Regeneron's four-year-old collaboration with CytomX Therapeutics has been significantly expanded, with the companies announcing a broadened agreement that...
Alnylam Pharmaceuticals commits USD 2b to generative AI siRNA discovery collaboration with Inceptive
Alnylam Pharmaceuticals (Nasdaq: ALNY) has committed up to USD 2 billion to embed generative AI into its siRNA discovery engine, entering a strategic...
DaltonTx launches agentic AI drug discovery platform with Sygnature Discovery collaboration
UK-based DaltonTx has launched its Dalton drug discovery platform and announced Sygnature Discovery as its first named CRO client, marking the public...
Mineralys repurchases Tanabe royalties on lorundrostat for USD 200m
Mineralys Therapeutics (Nasdaq: MLYS) has agreed to pay Tanabe Pharma Corporation USD 200 million upfront to extinguish all future royalty obligations on...
Spanish ADC firm Ona Therapeutics closes Series B round at USD 86.6m
Spain-based Ona Therapeutics has closed an oversubscribed USD 86.6 million Series B financing round to advance its antibody-drug conjugate (ADC) pipeline...
Jade Bio raises USD 150m via public offering to accelerate autoimmune antibody pipeline
San Francisco-based Jade Biosciences, Inc. (Nasdaq: JBIO) announced the pricing of a public offering of common stock to raise USD 150 million in gross...
Inventiva raises USD 120m equity, EUR 150m debt ahead of lanifibranor Phase III readout
France-based Inventiva (Euronext Paris and Nasdaq: IVA) announced a multi-part refinancing ahead of an anticipated Phase 3 readout for its lead MASH asset,...
Eli Lilly commits USD 1.9b to access Ascidian's RNA exon editing platform for kidney diseases
Eli Lilly (NYSE: LLY) has committed up to USD 1.9 billion to access Boston-based Ascidian Therapeutics' RNA exon editing platform for inherited kidney...
Contraline closes USD 92.5m Series B for male contraceptive gel development
Charlottesville, Virginia-based Contraline, Inc., a clinical-stage biopharmaceutical company developing male contraceptives, has closed a USD 92.5 million...
Travere picks up BTKi civorebrutinib from Everest Medicines in USD 1.14b deal
Travere Therapeutics (Nasdaq: TVTX) has committed USD 112.5 million upfront to license civorebrutinib, a covalent reversible BTK inhibitor developed by...
Ideaya and Roche to try out PRMT5 + pan-RAS inhibition against pancreatic cancer
South San Francisco-based Ideaya Biosciences (Nasdaq: IDYA) has entered a clinical collaboration with Roche to test whether combining an MTA-cooperative...
The AllSci Brief
Systematic R&D and deal news. Daily.